In Vivo and In Vitro Efficacy of an Acid-Sensitive Albumin Conjugate of Adriamycin Compared to the Parent Compound in Murine Renal-Cell Carcinoma

REFERENCES

• Greenfield, R. S., T. Kaneko, A. Daues, M. A. Edson, K. A. Fitzgerald, L. J. Olech, A. Grattan, G. L. Spitalny, and G. R. Braslawsky. 1990. In vitro eval- uation of Adriamycin immunoconjugate s synthesize d using an acid-sensitive hydrazon e linker. Cancer Res. 50:6600– 6607.
   Google Scholar
• Hillman, G. G., J. Droz, and G. H. Haas. 1994. Experimental animal model s for the study of therapeutic approache s in renal cell carcinoma. In Vivo 8:77– 80.
   Google Scholar
• Kratz, F., M. Hartmann, B. K. Keppler, and L. Messori. 1994. The bind- ing properties of two antitumor ruthenium(III) complexe s to apotransferrin. J. Biol. Chem. 269:2581 – 2588.
   Web of Science ®Google Scholar
• Kratz, F., U. Beyer, M. KruÈger, P. Schumacher, H. Zahn, T. Roth, H. H. Fiebig, and C. Unger. 1997a. Synthesis of new maleimide derivative s of daunorubici n and biological activity of acid labile transferrin conjugates. Biorg. Med. Chem. Lett. 7:617– 622.
   Google Scholar
• Kratz, F., I. Fichtner, U. Beyer, P. Schumacher, T. Roth, H. H. Fiebig, and C. Unger. 1997b. Antitumour activity of acid labile transferrin and albumin doxorubici n conjugate s in in vitro and in vivo human tumor xenograf t models. Eur. J. Cancer 33(suppl. 8): S175.
   Google Scholar
• Kratz, F., U. Beyer, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, U. Falken, and C. Unger. 1998a. Preparation, characterizatio n and in vitro eficacy of albumin conjugate s of doxorubicin. Biol. Pharm. Bull. 21:56– 61.
   Web of Science ®Google Scholar
• Kratz, F., U. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, C. Unger, and U. Falken. 1998b. Transferrin conjugate s of doxorubicin: Synthesis, characterization, cellular uptake, and in vitro eficacy. J. Pharm. Sci. 87:338– 346.
   Web of Science ®Google Scholar
• Kratz, F., T. Roth, I. Fichtner, H. H. Fiebig, and C. Unger. 1998c. Develop- ment of antitumor protein and polymer conjugate s using in vitro and in vivo tumor xenograf t models. In Relevance of tumor models for anticance r drug development, Contribution to oncology, 27 ed. H. H. Fiebig. Basel: Karger Verlag. Maeda, H., and Y. Matsumura. 1989. Tumoritropi c and lymphotropi c principles of macromolecula r prodrugs. Crit. Rev. Ther. Drug Carrier Sys. 6:193– 210.
   Google Scholar
• Mancilla-Jimenez, R. 1976. Papillary renal cell carcinoma: A clinical, radiolog- ical and pathologica l study of 34 cases. Cancer 38:2466 – 2469.
   Web of Science ®Google Scholar
• Matsumura, Y., and H. Maeda. 1986. A new concep t for macromolecula r ther- apeutics in cancer chemotherapy: Mechanism of tumoritropic accumulatio n of proteins of the antitumor agent smancs. Cancer Res. 46:6387– 6392.
   Web of Science ®Google Scholar
• Salup, R. R., and R. H. Wiltrout. 1986. Adjuvant immunotherapy of estab- lished murine renal cancer by interleukin 2 stimulated cytotoxic lymphocytes. Cancer Res. 46:3358 – 3363.
   Web of Science ®Google Scholar
• Sands, H., P. L. Jones, A. S. Shah, D. Palme, R. L. Vessella, and B. M. Gallagher. 1988. Correlation of vascular permeability and blood ¯ow with monoclona l antibody uptake by human clouse and renal cell xenografts. Cancer Res. 48:188–193.
   PubMed Web of Science ®Google Scholar
• Sayers, T. J., T. A. Wiltrout, McCormick K., Husted C., and Wiltrout R. H.. 1990. Antitumor effects of interferon and cinterferon on a murine renal cancer (Renca) in vitro and in vivo.Cancer Res. 50 5414–5420.
   Google Scholar
• Schuler, J., H. H. Fiebig, E. A. Sausville, and A. M. Burger. 1997. Characteriza- tion of vascular permeability in human tumor xenografts ÐIdentification of suitable tumor models to evaluate polymer conjugates. Int. Symp. Relevance of Tumor Models for Anticancer Drug Developmen t, p. 6, 15– 17 October, Tumor Biology Center, Freiburg, FRG.
   Google Scholar
• Sinn, H., H. H. Schrenk, A. Friedrich, U. Schilling, and W. Maier-Borst. 1990. Design of compound s having an enhanced tumour uptake, using serum albu- min as a carrier. Part 1. Nucl. Med. Biol. 17(Int. J. Rad. Appl. Instrum. B):819– 827.
   Google Scholar
• Takakura, Y., T. Fujita, M. Hashida, and H. Sezaki. 1990. Disposition charac- teristics of macromolecule s in tumor-bearin g mice. Pharm. Res. 7:339– 346.
   Google Scholar